Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer

Current Pharmaceutical Design

Volumn 19, Issue 5, 2013, Pages 940-950

  Avan, Amir ^a   Quint, Karl ^b   Nicolini, Francesco ^a   Funel, Niccola ^c   Frampton, Adam E ^d   Maftouh, Mina ^a   Pelliccioni, Serena ^c   Schuurhuis, Gerrit J ^e   Peters, Godefridus J ^a   Giovannetti, Elisa ^a  

^a Amsterdam Gastroenterology Metabolism   (Netherlands)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF PISA   (Italy)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

c Met pathway; Cancer stem cells; Crizotinib; Gemcitabine; Pancreatic ductal adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; CRIZOTINIB; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; HERMES ANTIGEN; MESSENGER RNA; NUCLEOTIDE; SCATTER FACTOR RECEPTOR; SULFORHODAMINE B; UVOMORULIN; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL MIGRATION; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; IMMUNOCYTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR MECHANICS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT TANDEM REPEAT; SIGNAL TRANSDUCTION;

EID: 84876744809     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804547312     Document Type: Article

References (53)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011; 378:607-20.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Li Y, Kong D, Ahmad A, et al. Pancreatic cancer stem cells: Emerging target for designing novel therapy. Cancer Lett 2012.
4. Sergeant G, Vankelecom H, Gremeaux L, et al. Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat Rev Clin Oncol 2009; 6: 580-6.
5. Hong SP, Wen J, Bang S, et al. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009; 125: 2323-31.
6. Ottinger S, Klöppel A, Rausch V, et al. Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract. Int J Cancer 2012; 130: 1671-81.
7. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-37.
8. Li C, Wu JJ, Hynes M, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141: 2218-27.
9. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311: 29-33.
10. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6: 1997-2003.
11. Stabile LP, Rothstein ME, Keohavong P, et al. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 2008; 7: 1913-22.
12. Dai C, Saleem MA, Holzman LB, et al. Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int 2010; 77: 962-73.
13. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011; 3(Suppl 1): S7-S19.
14. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6: 637-45.
15. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011; 60: 861-8.
16. Ebert M, Yokoyama M, Friess H, et al. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 1994; 54: 5775-8.
17. Zhu GH, Huang C, Qiu ZJ, et al. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci 2011; 56: 1090-8.
18. Di Renzo MF, Poulsom R, Olivero M, et al. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995; 55: 1129-38.
19. Logan-Collins J, Thomas RM, Yu P, et al. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res. 2010; 70:1130-40.
20. Quint K. Expression of cancer stem cell markers, multidrug resistance genes and regulators of epithelial-mesenchymal transition in gemcitabine resistant cells. Proceedings of 15th Annual Meeting on Surgical Research 15. Chirurgische Forschungstage; 2011 Sept 22.-24; Dresden, Germany.
21. Funel N, Giovannetti E, Del Chiaro M, et al. Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest 2008; 88: 773-84.
22. Avan A, Crea F, Paolicchi E, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells. Mol Cancer Ther 2012; 11: 1735-46.
23. Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol 2012; 23: 670-7.
24. Honeywell RJ, Giovannetti E, Peters GJ. Determination of the Phosphorylated Metabolites of Gemcitabine and of Difluorodeoxyuridine by LCMSMS. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1203-13.
25. Giovannetti E, Zucali PA, Assaraf YG, et al. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 2011; 105: 1542-53.
26. Peters GJ, van der Wilt CL, van Moorsel CJ, et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87: 227-253.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
28. Bijnsdorp IV, Giovannetti E, Peters GJ. Analysis of drug interactions. Methods Mol Biol 2011; 731: 421-34.
29. Mousavi SH, Moallem SA, Mehri S, et al. Improvement of cytotoxic and apoptogenic properties of crocin in cancer cell lines by its nanoliposomal form. Pharm Biol 2011; 49: 1039-45.
30. El Maalouf G, Le Tourneau C, Batty GN, et al. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 2009; 35: 167-174.
31. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5:19-33.
32. Bianco C, Giovannetti E, Ciardiello F, et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res. 2006;12:7099-107.
33. Elnaggar M, Giovannetti E, Peters GJ. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr Pharm Des 2012; 18: 2811-29.
34. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004; 363: 1049-57.
35. Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629-37.
36. Hallberg B, Palmer RH. Crizotinib--latest champion in the cancer wars? N Engl J Med 2010; 363:1760-2.
37. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010; 18: 548-51.
38. Fukuyoshi Y, Inoue H, Kita Y, et al. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 2008; 98: 1536-9.
39. Gandhi L, Janne PA. Crizotinib for ALK-rearranged Non-Small Cell Lung Cancer: A new targeted therapy for a new target. Clin Cancer Res 2012; 18: 3737-42.
40. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011; 6: 942-6.
41. Dai Y, Bae K, Pampo C, et al. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis 2012; 29: 253-61.
42. Nakajima S, Doi R, Toyoda E, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004; 10: 4125-33.
43. McInroy L, Määttä A. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun. 2007; 360: 109-14.
44. Handra-Luca A, Hong SM, Walter K, et al. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. Br J Cancer 2011; 104: 1296-302.
45. Thomas PA, Kirschmann DA, Cerhan JR, et al. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res 1999; 15: 2698-2703.
46. Danesi R, Altavilla G, Giovannetti E, et al. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics 2009; 10: 69-80.
47. Rudin D, Li L, Niu N, et al. Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination. J Drug Metab Toxicol. 2011; 2: 1-10.
48. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996; 24: 1340-6.
49. Frese KK, Neesse A, Cook N, et al. Nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discov 2012; 2: 260-9.
50. Giovannetti E, Mey V, Loni L, et al. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol Res. 2007; 55: 343-9.
51. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 1797-803.
52. Ciccolini J, Dahan L, Andre N, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemo-therapies. J Clin Oncol 2010; 28: 160
53. Ciccolini J, Mercier C, Dahan L, et al. Integrating pharmacogenetics into gemcitabine dosing-time for a change? Nat Rev Clin Oncol 2011; 8: 439-44.